Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 3, 1999, Pages 221-226

  Meropol, Neal J ^a,c   Sonnichsen, Daryl S ^b   Birkhofer, Martin J ^b   Ferreira, Irene ^b   Noel, Diane ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

Colorectal cancer; Ftorafur; Leucovorin; Tegafur; UFT

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; FLUOROURACIL; FOLINIC ACID; TEGAFUR; URACIL;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER RECURRENCE; COLORECTAL CANCER; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG RESPONSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; COLORECTAL NEOPLASMS; CROSS-OVER STUDIES; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TEGAFUR; URACIL;

EID: 0032943959     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050887     Document Type: Article

References (20)

1. Noncompartmental analysis based on statistical moment theory. In: Gibaldi M, Perrier D (eds) Pharmacokinetics. Marcel Dekker, New York 1982. pp 409-417
2. Anderson LW, Parker RJ, Collins JM, Ahlgren JD, Wilkinson D, Strong JM (1992) Gas chromatographic-mass spectrometric method for routine monitoring of 5-fluorouracil in plasma of patients receiving low-level protracted infusions. J Chromatogr 581: 195
3. Belz S, Frickel C, Wolfrom C, Nau H, Henze G (1994) High-performance liquid chromatograhic determination of methotrexate, 7-hydroxymethotrexate, 5-methyltetrahydrofolic acid and folinic acid in serum and cerebrospinal fluid. J Chromatogr 661: 109
4. Etienne M-C, Speziale N, Milano G (1993) HPLC of folinic acid diastereoisomers and 5-methyltetrahydrofolate in plasma. Clin Chem 39: 82
5. Fleming TR (1982) One-sided multiple testing procedures for phase II clinical trials. Biometrics 38: 143
6. Fujii S, Ikenaka K, Masakazu F, Shirasaka T (1978) Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and of 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann 69: 763
7. Fujii S, Kitano S, Ikenaka K, Shirasaka T (1979) Effect of coadministration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann 70: 209
8. Gonzalez-Baron M, Feliu J, de la Gandara I, Espinosa E, Colmenarejo A, Martinez-Martinez B, Blanco E, Garcia-Giron C, Jaurez F, Garrido P, Ordonez A, Zamora P (1995) Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. Eur J Cancer 31: 2215
9. Kawaguchi Y, Nagayama S, Masuda H, Yasuda A (1980) Studies on the metabolism of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil co-administered orally to tumor-bearing rats. Gann 71: 889
10. Maranuka T, Umeno Y, Yosida K, Nagamachi M, Minami Y, Fujii S (1980) High-pressure liquid chromatographic determination of ftorafur [1-(tetrahydro-2-furanyl)-5-fluorouracil and uracil in biological materials after oral administration of uracil plus ftorafur. J Pharm Sci 59: 1296
11. Meropol NJ, Rustum YM, Petrelli NJ, Rodriguez-Bigas M, Frank C, Ho DH, Kurowski M, Creaven PJ (1996) A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol 37: 581
12. Mori A, Bertoglio S, Guglielmi A, Aschele C, Bolli E, Tixi L, Rosso R, Sobrero A (1993) Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil. Cancer Chemother Pharmacol 33: 179
13. Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, Jones DV Jr, Markowitz AB, Abbruzzese JL, Bready B, Levin B (1994) Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12: 2296
14. Pazdur R, Covington WP, Brown NS, Lassere Y, Diaz-Canton E, Ho DH (1996) Comparative steady state pharmacokinetics of oral UFT versus protracted intravenous 5-fluorouracil (FU) (abstract). Proc Am Soc Clin Oncol 15: 474
15. Poon MA, O'Connell J, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tsechetter LK, Wiesenfeld M (1989) Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 10: 1407
16. Rustum YM, Trave F, Zakrzewski SF, Petrelli N, Herrera L, Mittelman A, Arbuck SG, Creaven PJ (1987) Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin. NCI Monogr 5: 165
17. Saltz LB, Leichman CG, Young CW, Muggia FM, Conti JA, Spiess T, Jeffers S, Leichman LP (1995) A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin: an active oral regimen for advanced colorectal cancer. Cancer 75: 782
18. JA, Szapary D, Wynn WT (1984) Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects. Cancer Res 44: 3114
19. Tralongo P, Di Mari A, Scibilia G, Bosco V, Giudice A, Respini D, Failla G (1995) Prolonged 5-fluorouracil infusion in patients with metastatic colon cancer pretreated with bolus schedule of the same agent. Anticancer Res 15: 635
20. Zhang Z-G, Rustum YM (1991) Effects of diastereoisomers of 5-formyltetrahydrofolate on cellular growth. Sensitivity to 5-fluoro-2′-deoxyuridine, and methylenetetrahydrofolate polyglutamate levels in HCT-8 cells. Cancer Res 51: 3476